Abstract
Predicting bladder cancer responses to PD-L1 inhibitors? A case report and overview for the busy clinician
Highlights
Case ReportPredicting bladder cancer responses to PD-L1 inhibitors?
Bladder cancer is the sixth most common form of cancer in the United States and ranks fourth among men. 81,190 new cases of bladder cancer and 17,240 deaths attributable to bladder cancer are predicted to occur in 2018 in the United States alone [1]
As of the beginning of this year, there have been five therapies targeting the PD-1/ PD-L1 axis approved for second-line treatment of metastatic urothelial cancer with two approved for first-line therapy in cisplatin-ineligible patients (Tables 1 and 2)
Summary
Predicting bladder cancer responses to PD-L1 inhibitors? A case report and overview for the busy clinician. Seranio N, Malkowicz SB, Aguarin L, Dorsey JF, Christodouleas J and Kao GD* Departments of Radiation Oncology and Urology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
